Background This is an updated version of a previously published review in The Cochrane
Library (2005, Issue 2) on'Megestrol acetate for the treatment of anorexia‐cachexia …

In cancer cachexia trials, measures of physical function are commonly used as endpoints.
For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be …

Chronic heart failure is a complex catabolic state that carries a devastating prognosis. The
transition from stable disease to cardiac cachexia is not well understood. Mechanisms that …

Purpose We systematically assessed the efficacy and safety of appetite stimulants in the
management of cancer-related anorexia. Literature databases were searched for …

Significant variation exists in the outcomes used in cancer cachexia trials, including
measures of body composition, which are often selected as primary or secondary endpoints …

Appetite is governed by peripheral hormones and central neurotransmitters that act on the
arcuate nucleus of the hypothalamus and nucleus tactus solitarius of the brainstem. Cancer …

This study aimed to assess the efficacy and safety of megestrol acetate (MA) in anorexia-
cachexia syndrome (ACS). Literature and relevant databases were searched for randomized …

Abstract In 1993, megestrol acetate (MA) was approved by the US Food and Drug
Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients …

Background The aim of the present study was to summarise evidence from scientific studies
on cancer anorexia-cachexia syndrome in order to assess and highlight the efficacy of high …

Among cancer patients, thrombosis and cachexia are major causes of morbidity and
mortality. Although the two may occur together, little is known about their possible …